Recent advances in novel lateral flow technologies for detection of COVID-19

102Citations
Citations of this article
211Readers
Mendeley users who have this article in their library.

Abstract

The development of reliable and robust diagnostic tests is one of the most efficient methods to limit the spread of coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, most laboratory diagnostics for COVID-19, such as enzyme-linked immunosorbent assay (ELISA) and reverse transcriptase-polymerase chain reaction (RT-PCR), are expensive, time-consuming, and require highly trained professional operators. On the other hand, the lateral flow immunoassay (LFIA) is a simpler, cheaper device that can be operated by unskilled personnel easily. Unfortunately, the current technique has some limitations, mainly inaccuracy in detection. This review article aims to highlight recent advances in novel lateral flow technologies for detecting SARS-CoV-2 as well as innovative approaches to achieve highly sensitive and specific point-of-care testing. Lastly, we discuss future perspectives on how smartphones and Artificial Intelligence (AI) can be integrated to revolutionize disease detection as well as disease control and surveillance.

Cite

CITATION STYLE

APA

Hsiao, W. W. W., Le, T. N., Pham, D. M., Ko, H. H., Chang, H. C., Lee, C. C., … Chiang, W. H. (2021, September 1). Recent advances in novel lateral flow technologies for detection of COVID-19. Biosensors. MDPI. https://doi.org/10.3390/bios11090295

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free